Feed / RVMD

Revolution Medicines, Inc.

RVMD

Healthcare · 203.82 +0.3% today

Isolated · not yet confirmedMarket checked 11 Sept, 15:55 GMT-4

Market read

Revolution Medicines, Inc.'s current read is isolated; its market group is not confirming.

No new filing conclusion is available. 0 of 37 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 13 directly disclosed connections are confirming.

Company+0.3% todayVolume comparison unavailable
Market group0 of 37 activeBiotechnology · unavailable
Disclosed network0 of 8 confirmingNo filing-linked name is confirming now
What would change this read
  • Interest expense tied to the Royalty Purchase Agreement increased by $12.2 million in the three months ended March 31, 2026 versus the same period in 2025.

Invalidation: The isolated read changes if RVMD's group or a disclosed connection begins moving with it.

Watch this read

Research brief

The story so far

Healthcare · Biotechnology

No new filing conclusion is available. 0 of 37 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 13 directly disclosed connections are confirming.

Evidence that supports

No thresholded supportive filing evidence is available yet.

Evidence that challenges

No thresholded adverse filing evidence is available yet.

What would clarify the read
  • Interest expense tied to the Royalty Purchase Agreement increased by $12.2 million in the three months ended March 31, 2026 versus the same period in 2025.

Company research

Understand the business, not just the ticker

As of Sep 12, 2026
Business model and earnings drivers

Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.

Key research questions
  • Which operating variable is changing?
  • Is that change durable, cyclical or one-off?
  • What evidence would disprove the current interpretation?
Annual periods8
Price observations328
Usable filing statements80
Verified relationships14
Evidence supporting the case
  • Credit and interest rates has repeated favorable evidence across 3 filings.
Evidence challenging the case
  • Diluted shares increased 13.3% in the latest annual period.
Questions before a position

No credible peer-relative valuation comparison is available yet.

Longer-term price context

Price as of Sep 11, 2026

203.82
6m+114.4%12m+403.9%24m
Annual trajectory

Reported annual revenue and per-share history. This is accounting history, not a forecast.

PeriodRevenueYoYDiluted EPSShare change
2021-12-31$29.4M-31.6%$-2.57+32.7%
2022-12-31$35.4M+20.4%$-3.08+10.7%
2023-12-31$11.6M-67.3%$-3.86+40.3%
2024-12-31$0-100.0%$-3.58+48.2%
2025-12-31$0$-5.95+13.3%

What management says matters

Persistent and emerging business drivers

Legal and regulatory exposurepositive · 4 filings
The Company’s projections of future Royalty Payments are subject to significant estimation uncertainty and are based on various assumptions, including expected commercial launch timelines, regulatory approval probabilities, and projected net product sales ove…
10-Q · May 6, 2026
Product pipeline and R&Dmixed · 4 filings
Stock-based compensation expense Total stock-based compensation expense related to stock options, RSUs and the ESPP by function was as follows: Three Months Ended March 31, 2026 2025 (in thousands) Research and development $ 44,638 $ 16,380 General and admini…
10-Q · May 6, 2026
Credit and interest ratespositive · 3 filings
Interest expense Interest expense increased by $12.2 million during the three months ended March 31, 2026 compared to the same period in 2025, reflecting non-cash interest expense and amortization of issuance costs associated with the Royalty Purchase Agreeme…
10-Q · May 6, 2026
Restructuring and cost reductionsmixed · 1 filings
The increase for the nine months ended September 30, 2025 was primarily due to a $2.8 million impairment of a long term asset acquired as part of the EQRx Acquisition in the first quarter of 2024.
10-Q · Nov 5, 2025

Valuation discipline

Descriptive valuation snapshot

Price/sales · EV/sales . Comparisons use only industry-matched filing peers.

Scenario scaffold

No usable price/earnings or price/sales multiple (need a fresh price).

Price action

How the market is pricing the story

203.82+0.3% today

Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 11 Sept, 15:55 GMT-4; this is a coverage limitation, not a flat-price conclusion.

Developments

No sourced recent-development timeline yet

Jodie has not returned a relevant primary source or news item for RVMD. This is an evidence-coverage gap, not a conclusion that nothing material happened.

Business and financial condition

Reported financial figures are not available yet

Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.

Filing analysis

No comparable filing assessment is available yet

Jodie has not yet found a suitable current-versus-prior filing comparison for RVMD. This does not mean the latest filing was neutral or immaterial.

Business ecosystem

The relationships behind RVMD

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

TNGXTango Therapeutics, Inc.partnerMay 6, 2026

Tango Collaboration 80 In November 2024, we entered into a clinical collaboration with Tango Therapeutics, Inc.

SNYSanofipartnerFeb 25, 2026

Sanofi collaboration agreement In June 2018, the Company entered into a collaborative research, development and commercialization agreement (the Sanofi Agreement) with Aventis, Inc.

Depended on by

TNGXTango Therapeutics, Inc.partnerMay 13, 2026

Clinical Trial Collaboration and Supply Agreements In November 2024, the Company and Revolution Medicines, Inc.

Filing peers

Companies whose filings use similar operating language.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks 17 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

RVMD is currently a Follower in the organic co-movement group Biotechnology. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.

This group is retained as the last observed read for RVMD; it is not active in the latest market snapshot.

Context history

Theme membership history

No durable theme membership has been observed for this name yet.